Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsFasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and EuropeanThe genetics and screening of familial hypercholesterolaemiaOptimizing Treatment of Familial Hypercholesterolemia in Children and AdolescentsDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersThe year in cardiology 2015: preventionPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilCCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDLLipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biologyTreatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH RegistryTime to improve statin prescription guidelines in low-risk patients?Relation between Liver Transaminases and Dyslipidaemia among 2-10 y.o. Northern Mexican ChildrenTemporal trends in lipid screening and therapy among youth from 2002 to 2012PCSK9 Inhibitors: A Technology Worth Paying For?Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse-led clinics.Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs?Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics.My Approach to the Patient With Familial Hypercholesterolemia.Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Advanced Imaging and Diagnostic Methods in the Assessment of Suspected Ischemic Heart Disease in Women.Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.Documenting family history in children with hypercholesterolaemia: A lost opportunity.Recent advances in genetic testing for familial hypercholesterolemia.GC-1: A Thyromimetic With Multiple Therapeutic Applications in Liver Disease.Knowns and unknowns in the care of pediatric familial hypercholesterolemia.Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia.Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.Atypical Presentation and Treatment Response in a Child with Familial Hypercholesterolemia Having a Novel LDLR Mutation.Detection and management of familial hypercholesterolaemia in primary care in Australia: protocol for a pragmatic cluster intervention study with pre-post intervention comparisons.Hypercholesterolaemia: optimal treatment by next-generation drugs?Modern prevention: genetic testing, vascular imaging, machine learning, and drug safety.New Treatments on the Horizon for Familial Hypercholesterolemia.A perspective for sequencing familial hypercholesterolaemia in African Americans.The Genetic Spectrum of Familial Hypercholesterolemia (FH) in the Iranian Population.An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".
P2860
Q26741078-1B851F79-FCC5-402B-AF4B-4A48C2D7BE12Q26749306-CF6535D8-9B87-42D4-8481-F1D051628691Q26753081-9F1382C1-26C9-47A1-B892-CAC66FED5ADEQ26798119-FE26979D-A6E5-4EAD-BDCF-1B15FDD02353Q28070296-51520EED-447E-475B-9BF9-C8A78DA90B28Q28072221-9BDE396D-721D-4119-8013-2D6BC202B0FEQ28073656-D399590F-4CEC-4C0E-81DD-B3C7695F2F62Q28084156-03F1B145-F660-403E-8628-9284E2CED8B6Q28975614-ECB1F152-2DDE-457E-8FA4-E70121E64C51Q30242031-9B03EBB2-F180-4A60-9C8E-038D4BDE06BBQ31063192-7F7CD7F7-8820-48CF-A53D-31498473BB51Q33811585-DD8FF342-73E7-4A86-9454-D01C707DC02DQ36024080-B63AA14A-CAA6-4B36-B465-9BC6C802DD40Q36034652-F718F952-00ED-45C9-A7A1-BCAC799AC314Q36754518-CCD8F7A4-E3C3-4753-9536-BFCF95E70A98Q36824103-7A1BB023-EFE2-4B50-A009-BCEE0EF2C28EQ37069579-8C7F478B-D1A8-407F-9A65-751E9982279DQ37723246-8392CFC5-B7D9-4D71-8B64-59F909A5499AQ37731770-1DF605A1-149D-41BE-9732-7D09DC3037E1Q38724969-EB126D40-929F-4042-9BA1-51125227BBEAQ38793246-C200A859-5015-4503-9F6C-94605E5963C7Q38839105-7EB4B0F9-92A1-49EE-9499-10FD936EC5ABQ38904539-A811F23B-E2A1-444F-A02B-0F5DC864811CQ39054740-B2C336F0-EC0A-4131-BFF3-F85202B41FB5Q39065523-49EA30D4-6C4C-4F24-9BBC-77E6D30633F9Q39317912-93457A84-B0AF-446A-B66A-38B66F80763EQ39387787-3278B5E5-E75A-48F8-B350-B720013587BCQ39431228-67E9B052-A49B-4BB7-AFF4-251DCBC290B8Q40102570-6CB2F5AC-5C7A-419B-8C53-DD1C917F8F15Q40227478-3DF107E0-B8AB-4232-95F7-F97CCC276473Q40757066-E11EE507-9245-469A-8665-61370E2A8BFAQ41544724-32DDEE52-B928-4A1F-AB22-3201784ED6CFQ41619218-9DF73DE6-68A3-4A7F-992D-10D68895EB6BQ42698475-E5B5B687-54FB-48A8-95DB-10964044D951Q43242038-BF06A9CB-38BC-4200-B022-5F736FEBEDB4Q45945965-93E6812C-42A2-4297-9A14-46B7BB234A60Q47098216-1C8C2C19-2B18-4B9D-9598-D24145A7995FQ47099598-5226C05F-1794-488F-BDE2-E46C4D775003Q47155313-85989428-1827-4F46-A46A-61A7EE9A7459Q47161967-BB809E49-1084-444B-8612-CEFE09627FD9
P2860
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Familial hypercholesterolaemia ...... izing detection and treatment.
@ast
Familial hypercholesterolaemia ...... izing detection and treatment.
@en
type
label
Familial hypercholesterolaemia ...... izing detection and treatment.
@ast
Familial hypercholesterolaemia ...... izing detection and treatment.
@en
prefLabel
Familial hypercholesterolaemia ...... izing detection and treatment.
@ast
Familial hypercholesterolaemia ...... izing detection and treatment.
@en
P2093
P2860
P50
P921
P356
P1476
Familial hypercholesterolaemia ...... izing detection and treatment.
@en
P2093
Albert Wiegman
Anton F H Stalenhoef
Erik S Stroes
European Atherosclerosis Society Consensus Panel
Frederick J Raal
G Kees Hovingh
Gerald F Watts
Henry N Ginsberg
Jan Albert Kuivenhoven
Joep C Defesche
P2860
P304
P356
10.1093/EURHEARTJ/EHV157
P50
P5008
P577
2015-05-25T00:00:00Z
2015-09-21T00:00:00Z